ADAM17 and breast carcinoma: In support of this notion, ADAM17 is overactivated or overexpressed in numerous human cancers, including NSCLC (and its major LAC subtype), colon carcinoma, breast cancer, hepatocellular carcinoma, HNSCC and gastric cancer [29,169,170,171,172,173,174,175,176,177].